Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 2, 2004, Pages 255-259

  Debes, Jose D ^a   Roberts, Rosebud O ^a   Jacobson, Debra J ^a   Girman, Cynthia J ^a,c   Lieber, Michael M ^a   Tindall, Donald J ^a,b   Jacobsen, Steven J ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER; CANCER RISK; CLINICAL FEATURE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FAMILY HISTORY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INTERVIEW; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SELF REPORT;

ADULT; AGED; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PEDIGREE; PROSTATIC NEOPLASMS;

EID: 1242336877     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-03-0093     Document Type: Article

References (25)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA. Cancer J. Clin., 52: 23-47, 2002.
2. Small, E. J. Advances in prostate cancer. Curr. Opin. Oncol., 11: 226-235, 1999.
3. Kelloff, G. J., Lieberman, R., Steele, V. E., Boone, C. W., Lubet, R. A., Kopelovich, L., Malone, W. A., Crowell, J. A., Higley, H. R., and Sigman, C. C. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology, 57: 46-51, 2001.
4. Pahor, M., Guralnik, J. M., Ferrucci, L., Corti, M. C., Salive, M. E., Cerhan, J. R., Wallace, R. B., and Havlik, R. J. Calcium-channel blockade and incidence of cancer in aged populations. Lancet, 348: 493-497, 1996.
5. Jick, H. Calcium-channel blockers and risk of cancer. Lancet, 349: 1699-1700, 1997.
6. Vezina, R. M., Lesko, S. M., Rosenberg, L., and Shapiro, S. Calcium channel blocker use and the risk of prostate cancer. Am. J. Hypertension, 11: 1420-1425, 1998.
7. Jan, C. R., Lee, K. C., Chou, K. J., Cheng, J. S., Wang, J. L., Lo, Y. K., Chang, H. T., Tang, K. Y., Yu, C. C., and Huang, J. K. Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells. Cancer Chemother. Pharmacol., 48: 37-41, 2001.
8. Rybalchenko, V., Prevarskaya, N., Van Coppenolle, F., Legrand, G., Lemonnier, L., Le Bourhis, X., and Skryma, R. Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating. Mol. Pharmacol., 59: 1376-1387, 2001.
9. Fraser, S. P., Grimes, J. A., and Djamgoz, M. B. A. Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate, 44: 61-76, 2000.
10. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A., and Lieber, M. M. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. J. Am. Med. Assoc., 270: 860-864, 1993.
11. Mason, R. P. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J. Am. Coll. Cardiol., 34: 1857-1866, 1999.
12. Mason, R. P. Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer (Phila.), 85: 2093-2102, 1999.
13. Sharifi, A. M., and Schiffrin, E. L. Apoptosis in vasculature of spontaneously hypertensive rats effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am. J. Hypertension, 11: 1108-1116, 1998.
14. Jesmin, S., Sakuma, I., Hattori, Y., Fujii, S., and Kitabatake, A. Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a Type II diabetic rat model. Diabetologia, 45: 402-415, 2002.
15. Batra, S., Popper, L. D., and Hartley-Asp, B. Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells. Prostate, 19: 299-311, 1991.
16. Gann, P. H., Daviglus, M. L., Dyer, A. R., and Stamler, J. Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol. Biomark. Prev., 4: 611-616, 1995.
17. Fitzpatrick, A. L., Daling, J. R., Furberg, C. D., Kronmal, R. A., and Weissfeld, J. L. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann. Epidemiol., 11: 534-542, 2001.
18. Lever, A. F., Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P. A., Murray, L. S., Reid, J. L., and Robertson, J. W. K. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet, 352: 179-184, 1998.
19. Olsen, J. H., Sorensen, H. T., Friis, S., McLaughlin, J. K., Steffensen, F. H., Nielsen, G. L., Andersen, M., Fraumeni, J. F., Jr., and Olsen, J. Cancer risk in users of calcium channel blockers. Hypertension, 29: 1091-1094, 1997.
20. Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P. A., Murray, L. S., Robertson, J. W. K., and Lever, A. F. Cancer risk of hypertensive patients taking calcium antagonists. J. Hypertens., 16: 119-124. 1998.
21. Roberts, R. O., Jacobson, D. J., Girman, C. J., Rhodes, T., Lieber, M. M., and Jacobsen, S. J. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin. Proc., 77: 219-225, 2002.
22. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J., and Coltman Jr., C. A. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med., 349: 215-224, 2003.
23. Panser, L. A., Chute, C. G., Guess, H. A., LarsonKeller, J. J., Girman, C. J., Oesterling, J. E., Lieber, M. M., and Jacobsen, S. J. The natural history of prostatism: the effects of non-response bias. Int. J. Epidemiol., 23: 1198-1205, 1994.
24. Jacobsen, S. J., Jacobson, D. J., Girman, C. J., Roberts, R. O., Rhodes, T., Guess, H. A., and Lieber, M. M. Natural history of prostatism: risk factors for acute urinary retention. J. Urol., 158: 481-487, 1997.
25. Roberts, R. O., Lieber, M. M., Rhodes, T., Girman, C. J., Bostwick, D. G., and Jacobsen, S. J. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status among Men. Urology, 51: 578-584, 1998.